Table 3

Patient and tumour characteristics of pT1a-pT1b tumours vs other stage I-II tumours in the NEMESI study
Pathological stage I-II (pT1a, pT1b excluded) pT1a, pT1b
N. of patients 1492 402
Distribution by age
18–34 23 (1.5%) 7 (1.7%)
35–49 384 (25.7%) 85 (21.1%)
50–69 754 (50.5%) 230 (57.2%)
≥ 70 331 (22.2%) 80 (19.9%)
Menopausal status
Pre- 465 (31.2%) 101 (25.1%)
Post- 1,014 (68.0%) 293 (72.8%)
Unknown 13 (0.9%) 8 (2.0%)
Node sentinel biopsy
Yes 903 (60.5%) 319 (79.3%)
No 589 (39.5%) 83 (20.7%)
Axillary nodal dissection
Yes 941 (63.1%) 137 (34.1%)
No 551 (36.9%) 265 (65.9%)
Grading
G1 120 (8.0%) 101 (25.1%)
G2 741 (48.7%) 221 (55.0%)
G3 589 (39.5%) 72 (17.9%)
Unknown 42 (2.8%) 8 (2.0%)
Proliferation index (Ki-67/MB1)
0–18% 707 (47.4%) 283 (70.6%)
19–29% 279 (18.7%) 52 (12.9%)
≥ 30% 461 (30.9%) 54 (13.4%)
Unknown 45 (3.0%) 13 (3.2%)
ER status
ER positive (≥ 10%) 1,215 (81.4%) 351 (87.3%)
ER negative (0–9%) 276 (18.5%) 51 (12.7%)
Unknown 1 (0.1%) 0 (0.0%)
PgR status
PgR positive (≥ 10%) 1,038 (69.6%) 300 (74.6%)
PgR negative (0–9%) 449 (30.1%) 101 (25.4%)
Unknown 5 (0.3%) 0 (0.0%)
Hormonal status*
ER and/or PgR positive 1,228 (82.3%) 354 (88.1%)
ER and PgR negative 263 (17.6%) 48 (11.9%)
Unknown 1 (0.1%) 0 (0.0%)
HER2 status**
Positive 279 (18.7%) 49 (12.2%)
Negative 1,185 (79.4%) 344 (85.6%)
Missing 28 (1.9%) 9 (2.2%)
pN status
pN0 836 (56.0%) 319 (79.4%)
pN1 (1–3) 477 (32.0%) 74 (18.4%)
pN2 (4–9) 113 (7.6%) 6 (1.5%)
pN3 (≥ 10) 66 (4.4%) 3 (0.7%)

* cut off: 10%

** HER2 status positive if: IHC 3+; or IHC 2+ and amplified by FISH,SISH,CISH; or amplified by FISH,SISH,CISH

Gori et al.

Gori et al. BMC Cancer 2012 12:158   doi:10.1186/1471-2407-12-158

Open Data